Genaera! Ausbruch??? (Nasdaq:GENR) - 500 Beiträge pro Seite

[Genaera]

Genaera! Bald gehts los





heute +16% Ich denke in den den nächsten Tagen kommt
eine positive Meldung!
diese vieleicht?
GENAERA CORP. GETS PHASE III SBIR GRANT ???
Ich glaub schon!

Förtsch hat die Aktie damals bei 3 Euro empfohlen
als spekulativer Tipp! Ich denke Ihr solltet
einsteigen bevor der Zug wieder abgefahren ist!




News

Genaera: Vielversprechend (Der Aktionär)
Aktien & Co


Die Experten von "Der Aktionär" stufen die Aktien des Biotechnologieunternehmens Genaera als spekulativ aber vielversprechend ein.

Bei der Aktie von Genaera handele es sich um ein ebenso spekulatives wie vielversprechendes Investment, das sich insbesondere für den risikoorientierten Anleger eigne. Da sich die verschiedenen Produkte des Unternehmens noch in unterschiedlichen Phasen der Entwicklung befänden, raten die Experten dazu, ein langfristig ausgerichtetes Engagement in Erwägung zu ziehen, um vom großen Kurspotential in vollem Umfang profitieren zu können.

Da der Titel an deutschen Börsenplätzen nur sehr sporadisch gehandelt werde, empfehlen die Experten von "Der Aktionär" dem interessierten Anleger, etwaige Kaufgesuche für Aktien von Genaera direkt an die Heimatbörse in den USA zu richten, wo die Aktie unter dem Kürzel GENR zu finden sei.

Analyst: Der Aktionär
WKN der Aktie: 883210
KGV 02e: k.A.
Besprechungskurs: 4,20 Euro
Kursziel: 11 Euro
Rating des Analysten: Vielversprechend


Diese Seite drucken
Quelle: Aktien & Co 21.12.2001 14:13:00

http://www.stockpickreport.com/cbs/index.asp?src=CBS&ss=GENR

[Ariminios]

Besprechungskurs 4.20

Kursziel 11

[Nadine77]

Guten Abend!

Hat jemand irgendwelche Informationen, warum der Kurs von Genaera heute so eingebrochen ist?

Vielen Dank.

Grüße Nadine

[feeli]

[Nadine77]

Hallo!

Hat irgendjemand in letzter Zeit Genaera genauer unter die Lupe genommen? Relativ hohe Umsätze, auch heute wieder!! Eventuell die Vorboten für eine erfreuliche Meldung??? :-)

Vielleicht hat ja noch jemand eine Meinung dazu.

Grüße

Nadine

[okujawa]

Hat irgendjemand Informationen ?
+ 56 % ist schon gewaltig.
Gruß
OK

[okujawa]

Heute wieder über 60 % in Amerika ????
Kennt keiner Neuigkeiten ?
Gruß
OK

[meislo]

Genaera Presentation Highlights Potential Benefit Of Anti-Inflammatory Aminosterols in Asthma
Monday May 19, 9:02 am ET


PLYMOUTH MEETING, Pa., May 19 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR - News) today presented a preclinical study demonstrating the potential use of aminosterols in preventing and treating asthma, at the meeting of the American Thoracic Society, held in Seattle, Washington.
ADVERTISEMENT


The study investigated the effects of the aminosterol, MSI-1432, on airway hyperresponsiveness (AHR, a measure of airway narrowing propensity) and the accumulation of airway eosinophil cells, in a murine asthma model. MSI-1432 was selected from a chemical library of aminosterols that was screened for the ability to block mitogen and antigen-induced proliferation and aggregation of lymphocytes. In this study, mice were sensitized to allergens intranasally over a 22-day period, and then treated daily with either MSI-1432, the glucocoritcoid dexamethasone, or placebo. MSI-1432 significantly inhibited antigen-induced AHR (p<0.01) and BAL eosinophilia (p<0.05), whereas DEX significantly inhibited BAL eosinophilia (p<0.01) but not AHR. These results suggest that aminosterols with anti-inflammatory and anti-adhesion properties may be effective therapeutics for asthma.

This research is funded through a two-year Phase II Small Business Innovation Research (SBIR) grant from the National Heart Lung and Blood Institute, National Institutes of Health, that was awarded to Genaera in February 2002, valued at approximately $800,000. This SBIR grant supports the development of a small molecule anti-inflammatory aminosterol therapeutic, and will be used to further develop lead compounds with the intent to identify a clinical candidate.

Kenneth J. Holroyd, MD, Executive Vice President and Chief Operating Officer of Genaera, commented, "These results suggest the possible use of aminosterols to prevent and treat asthma, and potentially other inflammatory diseases. Our lead compounds have demonstrated sufficient efficacy in preclinical models to encourage our pursuit of additional research to identify, as resources allow, a clinical candidate compound. Genaera is committed to progressing our current drug development programs in the clinic while simultaneously continuing aminosterol research through the SBIR grant. At the same time, these anti-inflammatory aminosterols are our current principal preclinical research effort, while we pursue other program specific funding."

Genaera`s discovery of natural aminosterols has been complemented by a research program that has produced and evaluated many synthetic aminosterols. These natural aminosterols and their synthetic analogues are being developed as a class of agents that are able to block cellular activation in specific cell types. Squalamine, the first natural aminosterol discovered, is a potent anti-angiogenic agent with specificity for activated endothelial cells, and is currently being evaluated in clinical trials for cancers and for "wet" macular degeneration.

Genaera Corporation is a biopharmaceutical company committed to developing medicines for serious diseases from genomics and natural products. Research and development efforts are focused on anti-angiogenesis and respiratory diseases. Genaera has three products in development addressing substantial unmet medical needs in major pharmaceutical markets. These include squalamine, an anti-angiogenesis treatment for cancer and eye disease; interleukin-9 antibody, a respiratory treatment based on the discovery of a genetic cause of asthma; and LOMUCIN(TM), a mucoregulator to treat the overproduction of mucus and secretions involved in many forms of chronic respiratory disease. For more information on Genaera, visit the company`s website at www.genaera.com.

This announcement contains forward-looking statements within

[okujawa]

Kennt jemand Neuigkeiten ?
Es ist ruhig geworden, seit ihr alle schon im Urlaub ?
Gruß
OK

[kingofcarpet]

kann mir jemand sagen warum Genaera in den letzten 40 Tagen so stark gestiegen ist,habe nie irgend welche News gefunden.
Danke

[Ramsess1]

Schaut euch mal Genaera (GENR)an sie steigt und steigt...

[Ramsess1]

Der neuer Renner unter der Biotechwerte???

http://www.investtech.com/main/di.php?CompanyID=10500818&fn=…

[Ramsess1]

uups schon wieder 12 Prozent gestiegen....

[Genaera]

Hallo, heute stelle ich eine Unentdeckte Biotechperle
vor! Lest mal unten den Bericht! Von dieser Biotechfirma
ist denke ich großes zu erwarten! Bitte fragt nicht jeden Tag wann die Aktie explodiert. Ich sehe diese Aktie als langfristigeres Invest! Hier fehlt nur eine neue Meldung,
oder packt sie auf Eure Watchliste!! Bei GENR (Nasdaq) hatte ich das gleiche Gefühl und bin bei 0,3$ rein und bei 4$ raus. seht mal meinen Bericht vom letzten Jahr zu GENR.
Würde die Aktie nicht empfehlen, wenn ich nicht mich informiert hätte. Geht mal auf die Internetseite ...

http://www.adviral.com/ADVR/index.htm

WKN: 873511 ADVANCED VIRAL RESEARCH CORP. REGISTERED SHARES DL -,00001

Kurs: 0,126 $
Börse: OTC BB





ADVR`s AVR118 Granted a Patent in China for the Treatment of AIDS

PRNewswire-FirstCall via Comtex/ -- Advanced Viral Research Corp. (ADVR) today announced that China has recently granted the Company a patent for the treatment of AIDS patients with AVR118 (formerly known as Product R). The claims in the patent awarded by China cover the administration of AVR118 in combination with other anti-HIV drugs.

As previously reported, preliminary results from an Israeli clinical trial indicate that AVR118, a novel immunomodulator, may improve the quality of life of the patient, including increasing appetite, weight gain or stability and activities of daily living. AVR118 is also believed to be useful in enhancing the therapeutic effectiveness of the HAART drugs, as well as serving to mitigate the toxicity of HAART drugs.

The United Nations currently estimates that there are 1.5 million HIV carriers in China. New HIV infections in China have been increasing annually by about 30%. Chinese officials and the United Nations have warned that 10 million people could be infected by 2020.

"A recent United Nations Report on China found that the world is `witnessing the unfolding of an AIDS epidemic of proportions beyond belief`," said Eli Wilner, Chairman of the Board of ADVR. "The report went on to note that China is on the verge of a catastrophe that could result in unimaginable suffering, economic loss and social devastation."

"This patent not only further protects ADVR`s intellectual property in a potentially large market, but also serves as an additional opportunity for us to broaden the awareness of what ADVR is attempting to accomplish in this therapeutic category," noted James T. D`Olimpio M.D. "The announcement of this patent can assist us in educating the world`s researchers about ways to combat AIDS." Dr. D`Olimpio is a leading expert in oncology research and treatment who has focused on the areas of symptom control, palliative care, and cancer cachexia. Dr. D`Olimpio serves as a consultant to ADVR helping the Company to communicate the clinical results of AVR118 and speaking on issues related cachexia. He also serves on the Company`s Scientific Advisory Board.

ADVR recently announced the preliminary results of an Israeli clinical trial from the first fifteen cachectic (body wasting) AIDS patients treated with the novel immunomodulator AVR118. The results midway in this trial, first publicly announced on November 10, 2003, showed improvement in appetite, weight gain or stability, and enhanced quality of life in all patients. None of the 15 patients reported any significant side effects from AVR118 therapy.

"The enhancement of quality of life and the increase in activities of daily living observed in cachectic AIDS patients treated with AVR118 in the Phase I/II clinical trial in Israel carries the promise of returning AIDS patients to productive activity and relieve the economic burden imposed by this disease on the individual and society. If ultimately proven in further clinical trials, the value of AVR118 therapy in populations suffering with AIDS may be especially important in third world countries that are experiencing explosive growth, such as China," stated Shalom Z. Hirschman, M.D., Chief Scientist at ADVR and author of the patent.

ADVR`s AVR118 represents a biopolymer chemistry that possesses novel immunomodulator activity. This peptide-nucleic acid, which to date has shown no indication of human toxicity, appears to stimulate the proinflammatory responses required to combat viral infections such as AIDS and human papilloma virus and to dampen aberrant autoimmune-type inflammatory responses, such as occur in patients with rheumatoid arthritis. Therefore, AVR118 has been termed a "switch-type" immunomodulator. AVR118 is in clinical trials in Israel for the treatment of cachexia (body wasting) in patients with AIDS.

For further information regarding Advanced Viral Research Corp., please visit our website at www.adviral.com.

Advanced Viral Research Corp., based in Yonkers, New York, is a biopharmaceutical firm dedicated to improving patients` lives by researching, developing and bringing to market new and effective therapies for viral and other diseases.

Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by the Company. AVR118 (Product R) is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue and/or complete the clinical trials of AVR118 or satisfy certain other conditions relating to clinical trials including obtaining adequate insurance on terms acceptable to the Company. The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.

[Genaera]

habe GENR am 13.01.03 23:31:30 empfohlen!!